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Abstract
Background: Metastatic renal cell carcinoma (RCC) presents a therapeutic challenge for clinicians because of the
unpredictable clinical course, resistance to chemotherapy or radiotherapy and the limited response to
immunotherapy.
Patients and Methods: We report a case of a 62-year-old woman who underwent nephrectomy for T4N0 RCC,
clear cell type, Fuhrman grade 3/4 in 1999. The patinet subsequently had multiple tumor recurrences.
Results: The patient underwent eight metastasectomies, including multiple partial left nephrectomies, right
adrenalectomy, a complete left nephrectomy, and distal pancreatectomy. She remains well and tumor free 12 years
after initial diagnosis.
Conclusion: Repeated resections after initial metastasectomy can be carried out safely and provide long-term
survival in selected patients with recurrent metastasis from RCC. The findings from our case indicate that close
follow-up for the early detection of recurrence and complete resection of metastases can improve the results after
repeated resection.
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Background
Renal cell carcinoma (RCC) accounts for 3% of adult
malignancies and 90% of neoplasms arising from the
kidney [1]. It is the sixth leading cause of cancer death
in the USA [2]. Approximately one-third of patients
diagnosed with RCC in the modern era are found to
have metastatic disease upon presentation, while at least
an additional one-third of all patients undergoing
nephrectomy for apparent clinically localized disease
will go on to develop metastatic disease [3,4]. The med-
ian time before a relapse after nephrectomy is 15
months, and 85% of relapses occur within 3 years [5].
Frequent sites include the lungs (75% of cases), regional
lymphatic nodes (65%), bone (40%), liver (40%) and
brain (5%) [4]. Unusual sites of metastases can be
involved, including the thyroid, pancreas, skeletal muscle
and skin or underlying soft tissue. Untreated patients
with metastatic RCC have a median survival of 6 to 12
months and a 5-year survival rate of < 20%. Shorter
interval between nephrectomy and the development of
metastases is associated with a poorer prognosis [4].
Late tumor recurrence occasionally occurs many years
after initial treatment.
The role of metastasectomy for the treatment of
metastasis from RCC is widely accepted [6]. However,
no consensus has been reached concerning the optimal
treatment strategies for patients that have already
undergone previous metastasectomy, and are later found
to have recurrent metastasis. Furthermore, no standard
has been proposed that enables adequate answers to
questions frequently encountered clinical conditions
regarding the benefits actually conferred by repeated
resection under the following circumstances: (i) recur-
rence found in different sites after initial metastasect-
omy, (ii) the feasibility of a third or even fourth
resection of metastasis.
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(including ipsilateral adrenal gland, contralateral kidney
and pancreas metastasis) after initial nephrectomy,
whom was successfully treated with repeated metasta-
sectomies. To our knowledge, this is the first report of
such a case. We review current literature on the role of
metastasectomy on management of metastatic RCC.
Case Presentation
62-year-old Caucasian female underwent right nephrect-
omy for T4N0 renal cell carcinoma, clear cell type,
Fuhrman grade 3/4 in 1999. In January 2001, a CT scan
revealed a right adrenal mass and multiple left side kid-
ney masses. She underwent left partial nephrectomy and
right adrenalectomy. At that time, the surgical pathology
showed renal cell carcinoma, clear cell type, Fuhrman
grade 3/4. The tumors were located in the upper and
lower portion of the left kidney. The surgical margin at
the upper portion kidney was positive. Right adrenal
masses were also excised which revealed adrenal gland
with metastatic renal cell carcinoma, clear cell type. Sur-
gical margin of adrenalectomy was negative. The patient
subsequently had repeated left partial nephrectomy per-
formed in 2004, and again in 2007 for tumor recur-
rences. The pathology revealed metastatic renal cell
carcinoma. On January 27, 2010, the patient underwent
left kidney radical nephrectomy, which revealed multifo-
cal renal cell carcinoma, clear cell type, Fuhrman grade
3/4. The largest tumor nodule was 2.5 cm, with tumor
extended focally to renal sinus adipose tissue. Tumor
located in 0.1 cm from the nearest soft tissue resection
margin. The patient was subsequently started on hemo-
dialysis after surgery. In May 2010, the patient under-
went evaluation for possible kidney transplant. During
the workup, an ultrasound of the abdomen showed a
hypoechoic nodule in the body of the pancreas. A CT
scan revealed multiple small enhancing nodules
throughout the pancreas, best seen on arteriography,
which suspicious for metastatic disease of the pancreas
(Figure 1). On September 20 2010, the patient under-
went distal pancreatectomy. Histologically, the tumor
consisted of cells arranged in trabecular and alveolar
structures with clear or eosinophilic granular cytoplasm,
compatible with a metastatic RCC, clear cell type, invol-
ving pancreatic parenchyma (Figure 2). The surgical
margin was negative. Postoperatively, the patient recov-
ered well. She developed recurrent ascites in 2011,
which was thought to be related to pancreatic fistula. In
July 2011, she underwent exploratory laparotomy, exten-
sive enterolysis, resection of distal pancreatic segment,
and repair of enterotomy, chronic pancreatic fistula ori-
ginating from distal retained pancreatic segment. Surgi-
cal pathology revealed chronic pancreatitis with focal
granulomatous inflammation, multiple lymph nodes
examined without any signs of malignancies. At last fol-
low-up in November 2011, she remains in good physical
conditions and tumor free.
Discussion
Metastatic RCC presents a particular therapeutic chal-
lenge for clinicians because of its resistance to che-
motherapy and radiotherapy as well as its limited
response to immunotherapy [3,4]. Recent advances in
understanding the molecular biology of RCC led to the
development of several targeted agents that showed
impressive anti-tumor efficacy and prolongation of pro-
g r e s s i o n - f r e es u r v i v a l .T h ei n t e g r a t i o no ft h e s ed r u g s
Figure 1 Radiological evaluation. A computed tomography of the
chest and abdomen demonstrated multiple small enhancing
nodules throughout the pancreas.
Figure 2 Histopathological evaluation. A histological examination
of the distal pancreas from pancreatectomy showing metastatic
renal cell carcinoma, clear cell type. A high-power view
(Hematoxylin and eosin, 100×) showed tumor cells are characterized
by epithelial cells with clear cytoplasm and a well-defined cell
membrane, interspersed within a highly vascularized stroma.
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of RCC. However, it has also created new controversy
concerning the necessity, patient selection, and timing
of surgery (nephrectomy, metastasectomy).
Surgical intervention in patients with metastatic RCC
can occur in two settings [6,7]: (1) cytoreductive
nephrectomy: to resect the primary tumor in the face of
unresectable metastatic disease prior to the initiation of
systemic therapy, or (2) metastasectomy: to render a
patient clinically free of all sites of metastases. Reports
to date that have demonstrated a role for resection of
RCC metastases have included primarily patients with
solitary metastases and/or disease in the lungs only
[7-9]. The patients with good performance status under-
going nephrectomy and subsequent complete metasta-
sectomy may experience prolonged survival, which
could be attributed to a combination of patient selection
factors and the surgical resections [7-11]. However, the
utility of metastasectomy in patients with multiple
metastases in the era of target therapy has not been well
defined. We report this unusual case in a female patient
who underwent eight operations for recurrent diseases
and remained disease-free twelve years after initial diag-
nosis, highlighting the tremendous heterogeneity in bio-
logic behavior of metastatic RCC and the role of surgery
in long term cancer control.
One of the largest studies on metastasectomy from
Memorial Sloan-Kettering Cancer Center [8] reported
278 patients undergoing resection of metastatic RCC
over a 13-year period. A multivariate analysis identified
factors independently predictive of survival were male
gender, disease-free interval > 1 year, single metastatic
foci (multiple unilateral lung metastases were considered
single), and complete metastasectomy. Investigators at
the Mayo Clinic reported a series of 41 patients with
metastasectomy over a 20-year period and found a 5-
year overall survival rate of 31%. This selected group of
patients had a prolonged disease-free interval with a
median of 27 months, and excluded patients with skele-
tal, nodal, and spinal cord metastases [9]. In a recent
Mayo study of 887 patients who underwent nephrect-
omy for RCC between 1976 and 2006 and subsequently
developed multiple metastatic lesions [10], the impact of
complete metastasectomy on survival was evaluated con-
trolling for the timing, location, and number of metas-
tases and for patient performance status. The results
indicated that complete resection of multiple RCC
metastases may be associated with long-term survival. A
review of experience from M. D. Anderson Cancer Cen-
ter reported 179 (8.5%) of 2100 patients who were
known to have metastatic RCC between 1984 and 1997
underwent resection for an apparently solitary meta-
static lesion [11]. The overall 5-year survival rate was
29%. Among the 40 patients with recurrent disease after
resection of a lung metastasis, 24 (60%) were able to
undergo a subsequent resection compared with only 14
(25%) of the 56 patients with recurrent bone metastasis.
The pancreas is an uncommon site of metastasis for
renal cell carcinoma, typically occurring years after
treatment of the primary tumor. When the metastatic
focus is isolated and the tumor can be resected in its
entirety, patients can experience excellent 5-year survival
rates. In a retrospective review of patients undergoing
pancreatic resection for renal cell carcinomas metastatic
to the pancreas or periampullary region between April
1989 and May 1999 at the Johns Hopkins Medical Insti-
tutions [12], of 10 patients who underwent pancreatic
resection for renal cell carcinoma metastases, six under-
went pancreaticoduodenectomy and two underwent dis-
tal pancreatectomy, whereas the two remaining patients
underwent total pancreatectomy for extensive tumor
involvement throughout the entire gland. The mean
time from nephrectomy for resection of the primary
tumor to reoperation for periampullary recurrence was
9.8 years (median 8.5 years). In a retrospective review of
Mayo experience of 23 patients (15 men and 8 women)
with RCC metastatic to the pancreas [13], the mean
interval between resection of the primary RCC and
detection of the pancreatic metastases was 116 months
(range, 1-295 months). In 18 patients (78%), the pan-
creatic metastases were diagnosed more than 5 years
after nephrectomy, surgical resection was carried out in
11 patients (7 distal and 3 total pancreatectomies and 1
distal pancreatectomy followed 4 years later by total
pancreatectomy), with 8 patients alive at a mean follow-
up of 4 years, 6 of whom remained free of recurrence.
Overall, 12 patients (52%) were alive at a mean of 42
months after diagnosis of metastatic disease.
The development of vascular endothelial growth factor
(VEGF) and the mammalian target of rapamycin
(mTOR) inhibitors have markedly improved progress
free survival in treatment naive and previously treated
patients with metastatic RCC. However, the novel thera-
pies are more likely to be cytostatic than cytotoxic, com-
plete and durable response are rare; chronic therapy are
required and side effects are unavoidable [14,15].
Although 40-70% of adverse events (AEs) are grade 1
and 2, 10-20% of patients develop grade 3 or 4 AEs
requiring dose reductions, drug holidays or treatment
discontinuation. In Phase III trials evaluating VEGF and
mTOR inhibitors, the most common grade 3 and 4 AEs
observed including hypertension, decreased left ventricu-
lar ejection fraction, hand-foot-syndrome and myelosup-
pression [16]. The long-term impact of these side effects
is a concern in RCC patients who are living longer and
receiving chronic sequential or combination therapy
[16,17]. There is a clear need to develop individualized
therapy for patients with metastatic RCC. Our case, in
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cessfully with repeated metastasectomies for multiple
recurrences, without systemic therapy during twelve
years follow-up.
Conclusions
In summary, literature and our experiences suggest sur-
gical resection of multiple recurrences may be worth-
while in selected patients, not only as a mean of local
control, but also as a strategy for long term disease con-
trol, without the burden ofl o n gt e r md r u gt h e r a p y .
Further molecular studies are needed to understand the
heterogeneity in biologic behavior of metastatic RCC,
which in turn may help develop a more rational way to
individualize therapy for patients with RCC.
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